about
Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor SystemEffects of Deep Brain Stimulation on Autonomic FunctionDiagnosing and treating neurogenic orthostatic hypotension in primary care.Self-reported autonomic symptoms in Parkinson's disease: properties of the SCOPA-AUT scale.Autonomic Function Impairment and Brain Perfusion Deficit in Parkinson's Disease.The impact of nonmotor symptoms on quality of life in patients with Parkinson's disease in TaiwanTreating non-motor symptoms of Parkinson's disease with transplantation of stem cellsOrthostatic hypotension: managing a difficult problem.Variation in Recent Onset Parkinson's Disease: Implications for Prodromal Detection.Recognition and treatment of autonomic disturbances in Parkinson's disease.Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension.Overview of the Anatomy, Physiology, and Pharmacology of the Autonomic Nervous System.Role of peripheral vascular resistance as an indicator of cardiovascular abnormalities in patients with Parkinson's disease.Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson's disease.Sympathetic skin response and heart rate variability in predicting autonomic disorders in patients with Parkinson diseaseDoes sympathetic dysfunction occur before denervation in pure autonomic failure?Diagnosis of multiple system atrophy.Lesion of medullary catecholaminergic neurons is associated with cardiovascular dysfunction in rotenone-induced Parkinson's disease rats.Structural and functional alterations of the heart in Parkinson's disease.Orthostatic Heart Rate Changes in Patients with Autonomic Failure caused by Neurodegenerative Synucleinopathies.Non-Motor Symptoms of Parkinson's Disease and Their Impact on Quality of Life in a Cohort of Moroccan Patients.Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.Autonomic dysfunction and white matter microstructural changes in drug-naïve patients with Parkinson's diseaseImpact of disease duration and cardiovascular dysautonomia on hypertension in Parkinson's disease
P2860
Q26999386-FEF081C1-70C3-4AC2-9C4E-5622798B57A3Q28079412-5F045AD6-B80A-4313-B867-B3B77CA0127AQ33165773-71714AA3-1C08-4CBF-9FC3-F9CF21AF7BBAQ33554528-64D5A898-8F8D-4429-9AEF-BA3D2DDB2575Q33774566-CBCC1EBF-6640-417D-8B0E-81556A074883Q36284387-B95698E9-422D-4BD1-8BF9-F688734FC7A6Q36790753-385A3358-860D-4F85-941C-A7EC79989245Q36943826-71903FCF-CFEB-4470-819E-1E98D5E189BFQ37054007-23C616AB-29DF-4340-A882-62639778E0DBQ38594855-D81523B2-9B93-44E6-ABE2-387BAA1A8B62Q38658416-2D96E371-C6CC-4011-B5A3-62942D0738DCQ38878230-708106ED-FF40-48CB-A00E-A76E14CD53FCQ40133555-5B24EB35-58F1-4B4E-A37A-C2CC24BDFF64Q41203349-38C23294-5F95-421D-B31F-720B95537724Q42116670-AB3E416B-7597-4260-AA63-FE5CC175FC59Q47377298-DB924A17-CF3B-4390-AED2-DA36B7F4AD6EQ47665262-CD85916E-4897-4261-A74E-9F2C7FA20A5FQ48090417-16FA2ED2-92E0-4F46-A886-B3728CF2FB9EQ50066781-00E89D4A-1EA0-4F9D-98B0-D642EA95F782Q50190547-3D7B0A65-46AC-43E6-BFA3-0B1B471A6036Q52579210-9FB17CB7-806C-4F25-BAE2-9EFB780FFD7CQ52672547-9A2C0865-6B27-4DC4-AAFF-89D6FEF2E701Q58743454-D1F1EDB0-C1CD-44E0-9B16-61E2746278AEQ59153352-CCD62EB6-E6E6-4042-9A48-8F7AA3473D68
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Dysautonomia in Parkinson disease
@ast
Dysautonomia in Parkinson disease
@en
Dysautonomia in Parkinson disease
@nl
type
label
Dysautonomia in Parkinson disease
@ast
Dysautonomia in Parkinson disease
@en
Dysautonomia in Parkinson disease
@nl
prefLabel
Dysautonomia in Parkinson disease
@ast
Dysautonomia in Parkinson disease
@en
Dysautonomia in Parkinson disease
@nl
P2860
P356
P1476
Dysautonomia in Parkinson disease
@en
P2093
David S Goldstein
P2860
P304
P356
10.1002/CPHY.C130026
P577
2014-04-01T00:00:00Z